Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

101.43 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,006
Open 101.43
Bid (Size) 101.19 (3)
Ask (Size) 101.24 (3)
Prev. Close 101.43
Today's Range 101.43 - 101.43
52wk Range 59.77 - 105.69
Shares Outstanding N/A
Dividend Yield 1.74%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
The study examined health care records for more than 41,000 people. 
Via Investor's Business Daily
Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
A recent extensive analysis by Truveta Research has  
Via Benzinga

Performance

YTD
+48.12%
+48.12%
1 Month
+5.22%
+5.22%
3 Month
+6.56%
+6.56%
6 Month
+24.81%
+24.81%
1 Year
+67.33%
+67.33%

More News

Read More
Only Have $100? 3 No-Brainer Stocks to Buy Right Now
Via InvestorPlace
Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments
Via Benzinga
BellRing Brands gets pumped on the Ozempic weight-loss trend
Via MarketBeat
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Peering Into Novo Nordisk's Recent Short Interest
Via Benzinga
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
Via The Motley Fool
Google Leads Five S&P 500 Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Could Ozempic Harm These 3 Medical Device Stocks?
Via The Motley Fool
Novo Nordisk's Wegovy Eyes Asian Market Debut Despite Supply Crunch
Via Benzinga
7 Stocks Set to Capitalize on the Coming Year-End Rally
Via InvestorPlace
This Is What Whales Are Betting On Novo Nordisk
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Technical Analysis observations.
Via Chartmill
$3,000 Invested in These 3 Top Stocks Could Make You Rich in 10 Years
Via The Motley Fool
Emmanuel Macron To Unveil Novo Nordisk Record $2.3B Investment In France's Health Sector
Via Benzinga
3 Healthcare Stocks to Scoop Up as They Change the Medical Landscape
Via InvestorPlace
Ozempic's Surging Demand Has Novo Nordisk Restricting It In Europe, Plus An Older Generation Diabetes Drug: What's Next?
Via Benzinga
3 Consumer Goods Stocks That Will Define the Next Decade
Via InvestorPlace
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
Via Benzinga
Topics ETFs
Don't overlook NYSE:NVO—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
Via The Motley Fool
3 Stock-Split Stocks Billionaires Are Buying Hand Over Fist
Via The Motley Fool
Eli Lilly Just Got One Step Closer to Dethroning Ozempic. Time to Buy the Stock?
Via The Motley Fool
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.